Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires.

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent HIV, the creator of the drug, Gilead Sciences, announced on Wednesday.

BOSTON, 19th June, 2025 (WAM) -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, has signed a Memorandum of Understanding (MoU) with Sanofi, a ...

Gilead Sciences Inc. said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a convenient new way to ward off infection in a wide range of people. In two ...

Sanofi and Regeneron Pharmaceuticals, Inc. presented positive results from the EVEREST phase 4 study of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. In ...

SOURCE RemeGen Co., Ltd NOTE: This content is not written by or endorsed by "KTLA", its advertisers, or Nexstar Media Inc. For inquiries or corrections to Press Releases, please reach out to Cision.

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750 million ...